We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2024 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Randox Showcases Pioneering Diagnostic Technologies at 2021 AACC Clinical Lab Expo

By LabMedica International staff writers
Posted on 28 Sep 2021

Randox Laboratories (Crumlin, UK) showcased its pioneering diagnostic technologies at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo, which saw breakthrough innovations shaping the future of clinical testing and patient care.

With more than 400 companies exhibiting, the 2021 AACC Clinical Lab Expo is the premier global laboratory medicine exposition. Among its diverse product range displayed at AACC 2021 were third party quality control solutions, diagnostic reagents which included many niche & superior performance assays, clinical chemistry analyzers, molecular diagnostic solutions for infectious diseases including COVID-19 and patented biochip technology. The revolutionary biochip is capable of simultaneously detecting hundreds of targets from a single patient sample. Complete patient profiling in this way facilitates faster patient testing, earlier diagnosis and improved patient pathways.


Image: Randox Showcases Pioneering Diagnostic Technologies at 2021 AACC Clinical Lab Expo (Photo courtesy of Randox Laboratories)
Image: Randox Showcases Pioneering Diagnostic Technologies at 2021 AACC Clinical Lab Expo (Photo courtesy of Randox Laboratories)

Randox also demonstrated its Qnostics range of molecular controls for infectious diseases comprising hundreds of characterized viral, bacterial and fungal targets covering a wide range of diseases and infections. Comprising hundreds of characterized viral, bacterial and fungal targets, the Qnostics range includes transplant associated diseases, respiratory diseases, blood borne viruses, sexually transmitted infections, gastrointestinal infections and central nervous system diseases. The products can be used in the daily monitoring of assay performance, linearity assessment, assay evaluation, validation and verification of new assays and staff training.

Also on display at the event were the company’s Acusera Anti-SARS-CoV-2 controls which support assay validation and routine performance monitoring of serological assays for COVID-19. Conveniently supplied in a liquid format, this control has unrivalled 30-day open vial stability, therefore keeping waste to a minimum.

Related Links:
Randox Laboratories


Gold Member
Hematology Analyzer
Swelab Lumi
Automated Blood Typing System
IH-500 NEXT
New
FLU/RSV Test
Humasis FLU/RSV Combo
New
Nuclear Matrix Protein 22 Test
NMP22 Test

Latest Immunology News

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Advanced Imaging Method Maps Immune Cell Connections to Predict Cancer Patients Survival

Computational Tool Predicts Immunotherapy Outcomes for Metastatic Breast Cancer Patients